Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Investor Presentation (June 2011)

27 slides from Questcor Pharmaceuticals's investor presentation, Jun 7, 2011

  1. Slide 1: Questcor June 2011

    NASDAQ: QCOR June 2011 Exhibit 99.1 NASDAQ: QCOR June 2011

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Note: Except for the historical information contained herein, this presentation contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performan

  3. Slide 3: Questcor: a biopharmaceutical company for serious, difficult-to-treat conditions

    3 Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions

  4. Slide 4: Questcor Overview

    4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $133M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • De

  5. Slide 5: History of Acthar

    5 History of Acthar 2000 2010 1950 1952 First Approved 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010 1950

  6. Slide 6: Significant Barriers to Entry

    6 Significant Barriers to Entry

  7. Slide 7: QCOR Strategy – Sell More Acthar

    7 QCOR Strategy – Sell More Acthar Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) To Be Announced in July 2011

  8. Slide 8: Acthar and MS

    8 Acthar and MS Acthar when “Steroids are not suitable” *Based on prescriptions written • Neurodegenerative disorder • Acute treatment for relapses • Treatment for 1-2 weeks* • $40K-$50K/Rx Acthar when “Steroids are not suitable”

  9. Slide 9: Multiple Sclerosis Potential Market

    9 Multiple Sclerosis All numbers based on internal company estimates. US only. $500M to $2B+ Potential Market $500M to $2B+ $500M to $2B+ Potential Market Potential Market

  10. Slide 10: MS Sales – Record of Consistent Growth

    10 MS Sales – Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which

  11. Slide 11: Strong Correlation – Sales Calls vs. Rxs

    11 Strong Correlation-Sales Calls vs. Rxs *MS call data approximate

  12. Slide 12: MS Trends

    12 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q1-2011 results – Q1-11 new paid Rxs up 120% vs. Q1-10 – MS accounts for well over 50% of QCOR net sales • Estimated $75M annualized run-rate – February set new MS Rx record – March up 51% over February • Q2-2011 trends remain strong – Q1 mome

  13. Slide 13: Acthar and Nephrotic Syndrome (NS)

    13 • Characterized by excessive spilling of protein from the kidney into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6 months* • $150K-250K/Rx Acthar and Nephrotic Syndrome (NS) *Based

  14. Slide 14: Estimated total: 20,000-25,000 patients

    Estimated total: 20,000-25,000 patients (QQUESTCOR”

  15. Slide 15: NS Sales

    15 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Q1 2011 NS Scripts: 18 • 14 different prescribers – Q1 momentum continuing into Q2 • Extended course of therapy results in growing future vial demand as new Rxs ramp up • Expanding the NS selling effort

  16. Slide 16: NS R&D Plans

    16 • Case series published in peer-reviewed journal – March 2011 • Other investigator initiated studies nearing completion – Anticipate data to be presented at ASN, November 2011 – Anticipate peer-reviewed publications in 2012 • Company sponsored dose response trial for idiopathic membranous nephrop

  17. Slide 17: Infantile Spasms

    17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by

  18. Slide 18: Acthar and IS

    18 • FDA approval 10/15/10 – 7 year orphan exclusivity for IS indication • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx

  19. Slide 19: IS Sales

    19 • Targeting select institutions • Significant variability in quarterly prescriptions • Q1-2011 sales within historic range – Acthar currently used to treat 40-50% of IS patients IS Sales • Targeting select institutions • Significant variability in quarterly prescriptions • Q1-2011 sales within hi

  20. Slide 20: Immediate Acthar Growth Opportunities

    20 Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates ** Represents approximately 4 times Q1 11 net sales by therapeutic area based on internal company estimates

  21. Slide 21: Financials

    21 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive

  22. Slide 22: Q1-2011 Financial Results

    22 Q1-2011 Financial Results Record Sales (up 40%) and Solid Earnings (EPS up 42%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 36.8 95% $16.4 $0.17 $26.2 92% $12.0 $0.12 Q1-2011 Q1-2010 Record Sales (up 40%) and Solid Earnings (EPS up 42%) • First quarter vials shippe

  23. Slide 23: Questcor is Cash Flow Positive

    23 Questcor is Cash Flow Positive Debt-free balance sheet Cash / ST Investments Accounts Receivable $133M* $20M 5/24/11 *After return of $78 million of cash to shareholders through share repurchases. Debt-free balance sheet Cash / ST Investments Accounts Receivable $133M* $20M 5/24/11

  24. Slide 24: Share Repurchases

    24 Share Repurchases: 15 Million Shares • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 61.7 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchases significantly improve EPS •

  25. Slide 25: Go Forward Plan - Sell More Acthar

    25 • Sustain effort and momentum with MS • Expand NS selling effort • Maintain and gradually grow IS sales • Develop other markets for Acthar – Acthar is its own pipeline with 15 other on-label and many possible other therapeutic uses – Announce next vertical market in July – Further define and deve

  26. Slide 26: Questcor is streamlined, focused & profitable

    Quesicor is streamlined, focused & profitable Acthar has sustainable com petitive advantages j Focus on substantial growth in MS and NS sales 20101S approval/label modernization Market sizes have good growth potential Cash flow positive/no debt (& QUESTCOR”

  27. Slide 27: June 2011

    NASDAQ: QCOR June 2011 NASDAQ: QCOR June 2011

Questcor Pharmaceuticals — Investor Presentation (June 2011) on 6ix